Stockscreener 앱 받기
2.94
2.97%
-0.09
시장 영업 전:
2.90
-0.04
-1.36%
Aclarion Inc 주식(ACON)의 최신 뉴스
Aclarion Inc. (ACON) Slides Amid Light Trading, Support at $2.96 in FocusMoney Flow - newsline.com
Aclarion (ACON) Chief Strategy Officer granted 55,000 RSUs vesting in 2027 - Stock Titan
Aclarion (ACON) director receives 20,000 RSUs vesting in 2027 - Stock Titan
Aclarion (NASDAQ: ACON) director receives 20,000 RSU equity grant - Stock Titan
Aclarion (ACON) CFO awarded 50,000 restricted stock units set to vest 2027 - Stock Titan
Aclarion (ACON) CEO Brent Ness receives 100,000 RSU equity award - Stock Titan
Aclarion (ACON) director awarded 20,000 RSUs vesting in 2027 - Stock Titan
Aclarion (ACON) grants 100,000 RSUs to Executive Chairman Thramann - Stock Titan
Aclarion (ACON) director receives 20,000 RSU equity award, total holdings 22,502 shares - Stock Titan
Director granted 20,000 RSUs at Aclarion (NASDAQ: ACON) vesting 2027 - Stock Titan
ACONW Warrants Surge Over 10%: A Closer Look at the Microcap MoveValue Area High - newsline.com
Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform - Ortho Spine News
Aclarion Inc. (ACON) Consolidates Near Key Support After Marginal DeclinePrice Target - newsline.com
Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub - The Manila Times
Aclarion Company Profile & Introduction - Moomoo
Aclarion partners with PRIA Healthcare on market access program By Investing.com - Investing.com South Africa
Aclarion partners with PRIA Healthcare on market access program - Investing.com
Aclarion enlists PRIA in push for insurer coverage of AI back-pain scans - Stock Titan
Aclarion waves off investor’s acquisition offer - BizWest
Echo Lake Capital cancelled the acquisition of Aclarion, Inc.. - marketscreener.com
Aclarion Comments on Echo Lake News - Baystreet.ca
Aclarion board rejects Echo Lake’s $4 per share takeover bid By Investing.com - Investing.com Australia
Aclarion board rejects Echo Lake’s $4 per share takeover bid - Investing.com
Aclarion Rejects Echo Lake Capital’S Unsolicited Acquisition Proposal - TradingView
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal - The Manila Times
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting - The Manila Times
Aclarion board: Echo Lake’s $4 bid uses company cash, favors buyer - Stock Titan
Back pain tech Aclarion cites 196% scan growth as investors back board - Stock Titan
Aclarion rejects unsolicited $4/share buyout proposal - grafa.com
Aclarion, Inc. 8-K SEC Filing June 2026 – Equity Incentive Plan Amendment Approved and Company Information - Minichart
Aclarion Stockholders Approve Directors and Equity Plan Amendment - TipRanks
Aclarion (ACON) shareholders elect board, ratify auditor and approve equity plan - Stock Titan
Aclarion partners with Los Angeles neuroscience clinic for study By Investing.com - Investing.com Australia
Aclarion partners with Institute of Neuro Innovation to expand Nociscan use for chronic low back pain diagnosis. - Pluang
Aclarion partners with Los Angeles neuroscience clinic for study - Investing.com
Aclarion Expands Nociscan Availability in Greater Los Angeles Through Partnership with Institute of Neuro Innovation - Quiver Quantitative
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation - marketscreener.com
Back-pain scan Nociscan helps pinpoint bad discs, now in L.A. - Stock Titan
Aclarion Inc. (ACON) Hovers Near Key Support Amid Minimal Price MovementHigh Yield Stocks - newsline.com
Aclarion's Nociscan tech reveals immune-linked back pain subtypes, expanding precision spine care potential. - Pluang
Aclarion’s Technology Shows Potential in Identifying Immune-Biomarkers in New Study - geneonline.com
Aclarion’s Nociscan technology used in back pain study By Investing.com - Investing.com South Africa
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study - The Manila Times
Aclarion's Nociscan Technology Linked to Immune Signatures in Back Pain Study, Expanding Clinical Applications - Quiver Quantitative
Aclarion’s Nociscan technology used in back pain study - Investing.com
ACON Maintained by Ascendiant Capital -- Price Target Raised to $7.50 - GuruFocus
SentinelOne To Rally Nearly 40%? Here Are 10 Analyst Forecasts For Friday - Benzinga
Aclarion Inc. Warrants (ACONW) Edge Lower as Tight Trading Range Persists at $0.03Algorithmic Stock Picks - The Legal Advocate
Aclarion: Board Will Determine Course of Action It Believes Is in Best Interests of Co, Hldrs >ACON - Moomoo
Aclarion to Review Echo Lake Capital’s Unsolicited Proposal - geneonline.com
Aclarion: Echo Lake Communication Contains Numerous Assertions Regarding Governance and Other Matters That Lack Important Context >ACON - Moomoo
Aclarion: Echo Lake Cap Offered to Acquire the Co for $4/Shr in Cash and Contingent Value Rights >ACON - Moomoo
Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal - The Manila Times
Aclarion, Inc. Responds to Echo Lake Capital's Acquisition Proposal and Reaffirms Commitment to Shareholder Value - Quiver Quantitative
Aclarion says board to review Echo Lake Capital's acquisition proposal - marketscreener.com
Aclarion Says Board To Review Echo Lake Capital's Acquisition Proposal - TradingView
2.22%
0.92%
자본화:
|
볼륨(24시간):